Posted by Michael Wonder on 03 Jun 2024
Tris Pharma receives US FDA approval for once daily Onyda XR (clonidine hydrochloride) extended release oral suspension, the first and only liquid non-stimulant ADHD medication
29 May 2024 - First non-stimulant ADHD medication, with nighttime dosing, adds to Tris Pharma’s established portfolio of leading ADHD therapies and reinforces company's commitment to individuals with ADHD.
Tris Pharma today announced the US FDA has approved Onyda XR (clonidine hydrochloride), a once a day extended release oral suspension with nighttime dosing, for the treatment of ADHD as a monotherapy or as an adjunctive therapy to approved central nervous system stimulant medications in paediatric patients six years and older.
